文献速递脑血管病外科神经重症

血流导向装置辅助栓塞破裂动脉瘤与出血并发症增加相关:蛛网膜下腔出血神经血管内治疗的预后因素与结局

Flow Diverter Assisted Embolization of Ruptured Aneurysms is Associated with Increased Hemorrhagic Complications: Prognostic Factors and Outcomes in Neuroendovascular Treatment of Subarachnoid Hemorrhages.
PubMed 文献 · World Neurosurg · 2025-05-09

基于2016至2021年美国全国住院患者样本,纳入62567例非创伤性蛛网膜下腔出血成人患者,其中409例(0.65%)接受血流导向装置(PED)治疗、6834例(10.9%)接受弹簧圈栓塞。PED组胃肠道出血(5.1% vs 2.2%,P<0.05)和呼吸道出血(3.2% vs 0.7%,P<0.001)发生率高于弹簧圈组,且脑积水(47.4% vs 56.5%,P<0.05)及外引流或分流置入(38.9% vs 48.4%,P<0.01)比例较低。校正混杂因素后,前交通动脉、后交通动脉和大脑中动脉来源的SAH更倾向选择弹簧圈栓塞。

要点

  • PED组胃肠道出血5.1% vs 弹簧圈组2.2%,呼吸道出血3.2% vs 0.7%,均高于弹簧圈组
  • PED组脑积水47.4% vs 弹簧圈组56.5%,外引流或分流置入38.9% vs 48.4%,均低于弹簧圈组
  • 前交通动脉来源SAH选择弹簧圈栓塞的OR为4.0(95%CI 2.87-5.90,P<0.001)

核心结论

  • 与弹簧圈栓塞相比,PED与更高的全身性出血并发症发生率相关,尤其是胃肠道出血和呼吸道出血。
  • 接受PED的患者需要仔细的患者选择和术后管理。

研究设计与样本

  • 回顾性分析2016至2021年美国全国住院患者样本(National Inpatient Sample)中主要诊断为非创伤性蛛网膜下腔出血的成人住院患者。
  • 共识别62567例SAH患者,其中409例(0.65%)接受PED、6834例(10.9%)接受弹簧圈栓塞,其余88%接受非血管内治疗。
  • 采用单变量和多变量分析,校正人口学特征、合并症状态和出血病因。

主要发现

  • PED组胃肠道出血5.1% vs 弹簧圈组2.2%(P<0.05),呼吸道出血3.2% vs 0.7%(P<0.001)。
  • PED组脑积水47.4% vs 弹簧圈组56.5%(P<0.05),接受外引流或脑室腹腔分流38.9% vs 48.4%(P<0.01)。
  • 校正混杂因素后,选择弹簧圈栓塞而非PED的预测因素包括前交通动脉来源SAH(OR 4.0,95%CI 2.87-5.90,P<0.001)、后交通动脉来源(OR 2.0,95%CI 1.90-3.63,P<0.001)和大脑中动脉来源(OR 2.02,95%CI 1.36-3.13,P<0.05)。

关键数值与推荐

  • PED组胃肠道出血5.1% vs 弹簧圈组2.2%(P<0.05)。
  • PED组呼吸道出血3.2% vs 弹簧圈组0.7%(P<0.001)。
  • PED组脑积水47.4% vs 弹簧圈组56.5%(P<0.05)。
  • PED组外引流或脑室腹腔分流置入38.9% vs 弹簧圈组48.4%(P<0.01)。
  • 前交通动脉来源SAH选择弹簧圈栓塞的OR为4.0(95%CI 2.87-5.90,P<0.001),后交通动脉为OR 2.0(95%CI 1.90-3.63,P<0.001),大脑中动脉为OR 2.02(95%CI 1.36-3.13,P<0.05)。

临床怎么用

  • 作者认为,接受PED的患者需要仔细的患者选择和术后管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuroendovascular interventions, including pipeline embolization device (PED)/flow diverter placement and coil embolization, are increasingly used in the management of nontraumatic subarachnoid hemorrhages (SAH). However, literature on trends, predictors of patient selection, and complications remains limited. This study aims to identify factors influencing treatment selection and risks associated with PED versus coil embolization in SAH. METHODS: The 2016 to 2021 National Inpatient Sample was used to identify adult inpatients with a primary diagnosis of nontraumatic SAH. Univariate and multivariable analyses adjusting for demographics, comorbidity status, and hemorrhage etiology were used to characterize statistical associations. RESULTS: Of 62,567 patients identified as having an SAH from 2016 to 2021, 409 patients (0.65%) underwent PED, and 6834 patients (10.9%) underwent coil embolization. The remaining 88% underwent nonendovascular management. Complications associated with PED placement and not coil embolization included gastrointestinal (5.1% vs. 2.2%; P < 0.05) and respiratory tract bleeding (3.2% vs. 0.7%; P < 0.001). Those who underwent PED were less likely to have hydrocephalus (47.4% vs. 56.5%; P < 0.05) and receive external ventricular drain or ventriculoperitoneal shunt placement (38.9% vs. 48.4%; P < 0.01). After controlling for confounding factors, predictors for receiving coil embolization instead of PED placement included SAH originating from the anterior communicating artery (odds ratio [OR]: 4.0; 95% confidence interval [CI]: 2.87-5.90; P < 0.001), posterior communicating artery (OR: 2.0; CI: 1.90-3.63; P < 0.001), and middle cerebral artery (OR: 2.02; CI: 1.36-3.13; P < 0.05). CONCLUSIONS: PED is associated with a higher incidence of systemic hemorrhagic complications, particularly gastrointestinal and respiratory tract bleeding, compared to coil embolization. Patients undergoing PED require careful patient selection and postprocedural management.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Pando A, Ha CJ, Thibault D, et al. Flow Diverter Assisted Embolization of Ruptured Aneurysms is Associated with Increased Hemorrhagic Complications: Prognostic Factors and Outcomes in Neuroendovascular Treatment of Subarachnoid Hemorrhages. World Neurosurg. 2025. PMID: 40349917. doi:10.1016/j.wneu.2025.124061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。